Summary
The transforming growth factor-β (TGF-β) family of ligands has a pivotal role as regulators of cell growth, differentiation and migration. Overexpression of TGF-β has been associated with breast, colon, hepatocellular, lung and pancreatic cancer. Importantly, overexpression of TGF-β correlates with tumor progression, metastasis, angiogenesis and poor prognostic outcome. Therefore, TGF-β signaling has emerged as an attractive target for the development of new cancer therapeutics. In a search for metabolites from fungi inhibiting the TGF-β dependent expression of a reporter gene in HepG2 cells, we found that trichodimerol, a previously isolated bisorbicillinoid, inhibited serine phosphorylation of the TGF-β activated Smad2/3 transcription factors and antagonized the cellular effects of TGF-β including reporter gene activation and expression of TGF-β inducible genes in HepG2 and MDA-MB-231 cells. In addition, trichodimerol blocked IFN-γ, IL-6 and IL-4 induced activation of Stat1, Stat3 and Stat6 transcription factors by inhibiting serine and tyrosine phosphorylation. In an in vitro angiogenesis assay, 20 μM trichodimerol completely abrogated the capillary-like tube formation of MDA-MB-231 cells on Matrigel.
Similar content being viewed by others
References
Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807–821 doi:10.1038/nrc1208
Li MO, Wan YY, Sanjabi S, Robertson A-KL, Flavell RA (2006) Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 24:99–149 doi:10.1146/annurev.immunol.24.021605.090737
Massague J, Seoane J, Wotton D (2006) Smad transcription factors. Genes Dev 19:2783–2810 doi:10.1101/gad.1350705
Gordon KJ, Blobe GC (2008) Role of transforming growth factor-β superfamily signaling pathways in human disease. Biochim Biophys Acta 1782:197–228
Feng X-H, Derynck R (2005) Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol 21:659–693 doi:10.1146/annurev.cellbio.21.022404.142018
Pardali K, Moustakas A (2007) Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775:21–62
Bierie B, Moses HL (2006) TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506–520 doi:10.1038/nrc1926
Leivonen S-K, Kähäri V-M (2007) Transforming growth factor-β signaling in cancer invasion and metastasis. Int J Cancer 121:2119–2124 doi:10.1002/ijc.23113
Bertolino P, Deckers M, Lebrin F, ten Dijke P (2005) Transforming growth factor-β signal transduction in angiogenesis and vascular disorders. Chest 128:585S–590S doi:10.1378/chest.128.6_suppl.585S
Wahl SM, Wen J, Moutsopoulos N (2006) TGF-β: a mobile purveyor of immune privilege. Immunol Rev 213:213–227 doi:10.1111/j.1600-065X.2006.00437.x
Yingling JM, Blanchard KL, Sawyer S (2004) Development of TGF-β signaling inhibitors for cancer therapy. Nat Rev Drug Discov 3:1011–1022 doi:10.1038/nrd1580
Iyer S, Wang Z-G, Akhtari M, Zhao W, Seth P (2005) Targeting TGFβ signaling for cancer therapy. Cancer Biol Ther 4:261–266
Pinkas J, Teicher BA (2006) TGF-β in cancer and as therapeutic target. Biochem Pharmacol 72:523–529 doi:10.1016/j.bcp.2006.03.004
Warr GA, Veitch JA, Walsh AW, Hesler GA, Pirnik DM, Leet JE, Lin PF, Medina IA, McBrien KD, Forenza S, Clark JM, Lam KS (1996) BMS-182123, a fungal metabolite that inhibits the production of TNF-alpha by macrophages and monocytes. J Antibiot (Tokyo) 49:234–240
White TJ, Bruns T, Lee S, Taylor AW (1990) Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds) PCR protocols: a guide to methods and applications. Academic, San Diego, pp 315–322
Erkel G, Belahmer H, Serwe A, Anke T, Kunz H, Kolshorn H, Liermann J, Opatz T (2008) Oxacyclododecindione, a novel inhibitor of IL-4 signaling from Exserohilum rostratum. J Antibiot (Tokyo) 61:285–290
Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091–3100 doi:10.1093/emboj/17.11.3091
Mikita T, Campbell D, Wu P, Williamson K, Schindler U (1996) Requirements for interleukin-4-induced gene expression and functional characterization of STAT6. Mol Cell Biol 16:5811–5820
Weidler M, Rether J, Anke T, Erkel G (2000) Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett 484:1–6 doi:10.1016/S0014-5793(00)02115-3
Pahl HL, Baeuerle PA (1995) A novel signal transduction pathway from the endoplasmatic reticulum to the nucleus is mediated by transcription factor NF-κB. EMBO J 14:2580–2588
Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729–3735
Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:2002–2007 doi:10.1093/nar/29.9.e45
Ke O, Costa M (2006) Hypoxia-Inducible Factor-1 (HIF-1). Mol Pharmacol 40:1469–1480 doi:10.1124/mol.106.027029
Giaccia A, Siim BG, Johnson RS (2003) Hif-1 as a target for drug development. Nat Rev Drug Discov 2:1–9 doi:10.1038/nrd1199
Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL (1997) TßRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 272:27678–27685 doi:10.1074/jbc.272.44.27678
Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH (1997) Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 272:28107–28115 doi:10.1074/jbc.272.44.28107
Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF (1997) Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA 94:10669–10674 doi:10.1073/pnas.94.20.10669
Chen CR, Kang Y, Massague J (2001) Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor β growth arrest program. Proc Natl Acad Sci USA 98:992–999 doi:10.1073/pnas.98.3.992
Zhang S, Zhang D, Sun B (2007) Vasculogenic mimicry: current status and future prospects. Cancer Lett 254:157–164 doi:10.1016/j.canlet.2006.12.036
Mazzucco CE, Warr G (1996) Trichodimerol (BMS-182123) inhibits lipopolysaccharide-induced eicosanoid secretion in THP-1 human monocytic cells. J Leukoc Biol 60:271–277
Nam J-S, Terabe M, Mamura M, Kang M-J, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM (2008) An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68:3835–3643 doi:10.1158/0008-5472.CAN-08-0215
Lee K, Roth RA, LaPres JJ (2007) Hypoxia, drug therapy and toxicity. Pharmacol Ther 113:229–246 doi:10.1016/j.pharmthera.2006.08.001
Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26:281–290 doi:10.1007/s10555-007-9066-y
von Gersdorff G, Susztak K, Rezvani F, Bitzer M, Liang D, Boettinger EP (2000) Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor β. J Biol Chem 275:11320–11326 doi:10.1074/jbc.275.15.11320
Kaminska B, Wesolowska A, Danilkiewicz M (2005) TGF beta signaling and its role in tumor pathogenesis. Acta Biochim Pol 52:329–337
Dumont N, Arteaga CL (2000) Transforming growth factor-beta and breast cancer: tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2:125–132 doi:10.1186/bcr44
Döme B, Hendrix MJC, Paku S, Tóvári J, Tímár J (2007) Alternative vascularization mechanisms in cancer. Am J Pathol 170:1–15 doi:10.2353/ajpath.2007.060302
Hendrix MJC, Seftor EA, Hess AR, Seftor REB (2003) Vasculogenic mimicry and tumor-cell plasticity: lessons from melanoma. Nat Rev Cancer 3:411–421 doi:10.1038/nrc1092
Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P (2005) Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7:R422–R435 doi:10.1186/bcr1019
Reich NC, Liu L (2006) Tracking Stat nuclear traffic. Nat Rev Immunol 6:602–612 doi:10.1038/nri1885
Decker T, Kovarik P (2000) Serine phosphorylation of STATs. Oncogene 19:2628–2637 doi:10.1038/sj.onc.1203481
Yu H, Jove R (2004) The Stats of cancer-new molecular targets come of age. Nat Rev Cancer 4:97–105 doi:10.1038/nrc1275
Chen Z, Han ZC (2008) Stat3: a critical transcription activator in angiogenesis. Med Res Rev 28:185–200 doi:10.1002/med.20101
Deng J, Grande F, Neamati N (2007) Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 7:91–107 doi:10.2174/156800907780006922
Klampfer L (2006) Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6:107–121 doi:10.2174/156800906776056491
Stocking EM, Williams RM (2003) Chemistry and biology of biosynthetic Diels–Alder reactions. Angew Chem Int Ed 42:3078–3115 doi:10.1002/anie.200200534
Lee D, Lee JH, Cai XF, Shin JC, Lee K, Hong Y-S, Lee JJ (2005) Fungal metabolites, sorbicillinoid polyketides and their effects on the activation of peroxisome proliferator-activated receptor γ. J Antibiot (Tokyo) 58:615–620
Acknowledgements
This work was supported by a grant from the Stiftung Rheinland-Pfalz für Innovation. We are very thankful to Prof. H. Anke for providing the crude extracts for the screening as well as Trichoderma longibrachiatum strain 049-2000. We thank Prof. S. Dooley, Medical Faculty of Mannheim, for providing the (AGCCAGACA)9MLP-Luc reporter plasmid, Prof. B. Brüne, University of Frankfurt, for providing the HepG2-pH3SVL cells, and Prof. O. Sterner, University of Lund, for the structure elucidation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Serwe, A., Anke, T. & Erkel, G. The fungal secondary metabolite trichodimerol inhibits TGF-β dependent cellular effects and tube formation of MDA-MB-231 cells. Invest New Drugs 27, 491–502 (2009). https://doi.org/10.1007/s10637-008-9201-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-008-9201-9